Moraiya

Management is aiming for a single-digit growth in the US market for FY24 on the back of launches from the Moraiya facility.

Cadila: Biosimilars, oncology portfolio hold promise for medium term

The Moraiya plant’s pending USFDA approval is crucial for Cadila’s US ambition

Cadila: Unfolding vaccine opportunity can offset US headwinds

For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables

Cadila: More a COVID hedge in the near term

Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility

Market Week Ahead: Volatility likely on expiry; TCS buyback eyed

Volatility is largely expected in the coming short trading week as there is expiry of February derivative contracts on Thursday but upside can't be ruled out as investors closely watch assembly elections in five states, which are crucial for ruling party BJP, especially after demonetisation.

Cadila shares extend gains, surge over 7%

The healthcare firm's stock rose after the US health regulator inspected its Moraiya plant and found it in compliance with manufacturing norms.

Analysts give a thumbs-up to Cadila on resolution of FDA warning

Brokerage firms and analysts tracking the stock welcomed the development and most have raised the target price. To be sure a lot of them were expecting resolution of the warning letter on Moraiya facility in the fourth quarter of FY17.

Cadila gains on resolution of its Moraiya plant warning letter

The company said it did not receive any observations from USFDA for its Moraiya facility, indicating successful resolution of the warning letter and thereby expects major boost to its US business.

Pricing pressure in US biz cyclical in nature: Cadila Health

In an exclusive interview with CNBC-TV18, Pankaj Patel said that the pricing pressure in US is cyclical in nature and competition is going to exist in the generic medicine market in US.

Cadila to complete remediation for Moraiya unit by Sep: Sources

The company had received warning letters for Moraiya and Zyfine plants in December last year. Zyfine facility, however, will take another 3-4 moths for remediation, sources say.

Credit Suisse downgrades Cadila; Moraiya clearance key to growth

Credit Suisse has downgraded Cadila Healthcare to neutral as the stock is already factoring in clearance of the Moraiya facility and any delay could impact high recovery assumed in FY18. It has cut multiple for the US generic business as it expects further impact to generics from more channel consolidation.

Pick Britannia; PNC Infratech looks interesting: Pankaj Sharma

In an interview to CNBC-TV18, Pankaj Sharma of Equirus Securities shares his views on FMCG space and expects better volumes with Britannia Industries as a good choice.

WHO red flag on Cadila to cost Rs 30-35cr revenues: Analyst

The World Health Organization (WHO) has issued a Notice of Concern to Cadila Healthcare over a unit in its Moraiya plant that manufactures vaccines.

Cadila Healthcare up 4%, begins supply to US from Ahmedabad unit

Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to market Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg. The drug falls in the anti-bacterials segment.

No data integrity issue at Moraiya facility: Cadila Health

Pankaj R Patel, CMD, Cadila Healthcare, said there are no data integrity issues with the Moraiya facility. He said the company plans to give additional information to the US FDA to address the Moraiya issue

2016 will be about stocks and not sectors: Kotak AMC

Nilesh Shah, managing director of Kotak Mahindra Asset Management is bullish on urban consumption on the back of the benefits that will accrue due to the implementation of 7th Pay Commission

Cadila dips 2%; Credit Suisse downgrades, sees 19% downside

Credit Suisse has raised concerns about Cadila's Moraiya facility in Gujarat as it feels that the unit may not get clearance before the end of the fiscal year.

Cadila Healthcare jumps after US FDA clears Moraiya plant

Shares of pharma major Cadila Healthcare surged over 5% on Tuesday morning after the US Food and Drugs Administration (FDA) gave a clearance to the company's facilities at Moraiya in Gujarat.